Heterocyclic compounds and methods for treating cancers expressing sulfotransferase (SULT) enzymes
Heterocyclic compounds selectively activated by SULT1 enzymes provide targeted antitumor activity in SULT1-positive cancers, addressing the need for precision oncology treatments with high efficacy and reduced toxicity.
Patent Information
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- UP THERAPEUTICS LLC
- Filing Date
- 2025-12-12
- Publication Date
- 2026-07-02
AI Technical Summary
There is an urgent need for precision oncology treatments that selectively target SULT1-positive cancers with high efficacy and minimal toxicity, as existing therapies often cause off-target toxicity due to non-specific activation in normal tissues.
Development of heterocyclic compounds that are selectively activated by SULT1 enzymes, forming cytotoxic metabolites in SULT1-high cancer cells while remaining inactive in SULT1-negative tumors, thereby minimizing off-target effects.
The compounds demonstrate potent antitumor activity in SULT1-expressing cancers with minimal toxicity to normal tissues, providing a targeted therapeutic approach.
Smart Images

Figure IMGF000003_0001 
Figure IMGF000003_0002 
Figure IMGF000004_0001